The MarketReader Minute
πArdelyx Faces Regulatory Setback, Arcturus Advances in Phase 2, Abbvie Under Pressure | Biotech Sector Insights
REGN, GILD, AMGN, INCY, and BIIB all showing negative returns. Of note is a class-action lawsuit against Biogen Inc., impacting financials and reputation; investors may seek recovery through Levi & Korsinsky until July 22, 2024.